Assessment for a COVID-19 oral anti-viral medication

New temporary Medicare Benefits Schedule (MBS) telehealth phone consultation item to assist practitioners treating COVID-19 positive patients

Page last updated: 18 July 2022

Commencing 19 July 2022, and available until 31 October 2022, two new temporary MBS item have been made available to support medical practitioners with treating COVID-19 positive patients.

The two new items 93716 (for General Practitioners) and 93717 (for Other Medical Practitioners) will be available for medical practitioners working in a general practice setting to assess a patients suitability to receive a prescription for a COVID-19 oral antiviral treatment via a telehealth phone consultation lasting at least 20 minutes (25 minutes for OMPs). The new items are specific to services for eligible Medicare patients nationally who have confirmed their COVID-19 infection via a laboratory test (PCR) or by a Rapid Antigen Test.

The Medicare benefits for the new temporary items will be paid at 85% of the schedule fee and are equivalent to the benefit paid for other time-tiered consultation items of equivalent duration

Further information is available in the following fact sheet.

PDF version Medicare assessment for COVID-19 oral anti-viral treatment (PDF 222 KB)
Word version Medicare assessment for COVID-19 oral anti-viral treatment (Word 131 KB)



In this section